Navigation Links
US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
Date:8/16/2009

.

Extavia should be used with caution in patients with depression. Injection site necrosis has been reported in 4% of patients in controlled trials. Typically, injection site necrosis occurs within the first four months of therapy. Necrosis may occur at a single injection site or multiple injection sites. Patient understanding and use of aseptic self-injection techniques and procedures should be periodically reevaluated, particularly if injection site necrosis has occurred. Anaphylaxis has been reported as a rare complication of interferon use. Other allergic reactions have included dyspnea, bronchospasm, tongue edema, skin rash, and urticaria.

The rate of flu-like symptom complex was approximately 57% in the four controlled clinical trials. The incidence decreased over time, with only 10% of patients reporting flu-like symptom complex at the end of the studies. Monitoring of complete blood and differential white blood cell counts, platelet counts and blood chemistries, including liver function tests, are recommended at regular intervals.

The most commonly reported adverse reactions are lymphopenia, injection site reaction, asthenia, flu-like symptom complex, headache and pain. Based on all the available evidence, the relationship between antibody formation and clinical safety and efficacy is not known. Female patients should be warned about the potential risk to pregnancy. The mechanism of action of interferon beta-1b in patients with multiple sclerosis is unknown. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms. Patients should be advised of the importance of rotating injection sites.

* Novartis gained the rights to seek approval for its own branded version of interferon beta-1b through agreements with Bayer Schering, the company that markets Betaseron.

Betaseron is marketed under the name of Betaferon(R) outside
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
2. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
3. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
4. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
5. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
6. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
7. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
8. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
9. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
10. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
11. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Suisse, October 1, 2014 ... et dans le domaine de l,analyse des données ... aujourd,hui une solution de diagnostic in vitro (IVD) ... analyse complète de la mucoviscidose dans un seul ... de caractériser tous les types de variantes par ...
(Date:9/30/2014)... report analyzes the worldwide markets for Enteral Feeding Devices in ... Nasogastric Tubes, and Others. The report provides separate ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for the period ... for these markets. The report profiles 38 companies ...
(Date:9/30/2014)... Sept. 30, 2014 MiMedx Group, Inc. (NASDAQ: ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental ... , Ph.D., Chief Scientific Officer, will present at the ... present on Tuesday, October 7, 2014, at 5:00PM Pacific ...
Breaking Medicine Technology:Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19MiMedx to Present at the Stem Cell Meeting on the Mesa 2
... Feb. 14, 2011 Thoratec Corporation (Nasdaq: THOR ... to save, support and restore failing hearts, announced today that ... to $100 million of the company,s shares of common stock ... confidence in the long-term strength of the company, as well ...
... 14, 2011 Mesa Laboratories, Inc. (Nasdaq: ... has declared a regular quarterly cash dividend of 12 ... 15, 2011 to shareholders of record at the close ... Laboratories develops, acquires, manufactures and markets electronic instruments and ...
Cached Medicine Technology:Thoratec Corporation Authorizes $100 Million Share Repurchase Program 2Thoratec Corporation Authorizes $100 Million Share Repurchase Program 3
(Date:10/1/2014)... and ATLANTA (PRWEB) October 01, 2014 ... security executive networking and relationship-marketing firm, announced ... Information Security Executive® and Project of the ... top-ranking decision makers representing organizations in financial ... Projects include large-scale technology endeavors that address ...
(Date:10/1/2014)... Beverly Hills licensed Clinical Psychologist and ... 20 years of private practice in her Beverly Hills ... achieve greater joy and fulfillment in their relationships. Dr. ... and suggestions for anyone who suspects they are in ... it or not, it’s not always easy to know ...
(Date:10/1/2014)... 01, 2014 NoteSwift Inc., announced today ... 10.0, 12.1 and 13.0. NoteSwift is the bridge between ... to navigate and document clinical information at the point ... creating a patient note by more than half – ... major pain points providers state impedes EHR use according ...
(Date:10/1/2014)... Ethiopia, at the occasion of the Leishmaniasis East ... African and international leishmaniasis experts, results of a ... monitoring plan, carried out by MSF, DNDi, ... Ethiopia, were presented to key decision makers in ... kala-azar with the combination of Sodium Stibogluconate and ...
(Date:10/1/2014)... Dr. Saj Jivraj, one of the ... traveling to Chennai, India, tomorrow to speak at the ... 3. , Dr. Jivraj is founder of the Anacapa ... and one of the world’s foremost prosthodontists, meaning he ... is speaking to the Indian Society of Oral Implantologists ...
Breaking Medicine News(10 mins):Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... 12 DARA,BioSciences, Inc. ("DARA") and Point Therapeutics, Inc. ... effective as,of the close of business on February 12, ... the respective stockholders,of DARA and Point. Immediately prior to ... split of its common stock pursuant to which,each 40 ...
... Ohio, Feb. 12 AtriCure, Inc.,(Nasdaq: ATRC ), ... surgical,ablation products, announced today that David J. Drachman, President ... Roth Capital,Partners 20th Annual OC Growth Stock Conference at ... Wednesday, February 20th at 2:00 p.m.,PT., A live ...
... tumors tend to survive longer and are more responsive ... to a study published online February 12 in the ... , Human papillomavirus has been shown to be involved ... particularly cancers of the upper throat, or oropharynx. Retrospective ...
... Deaths More Common Among Breast Cancer Survivors ... at greater risk of death from non-cancer causes ... cancer treatments improve, patients are surviving longer, and ... cancer. Judith-Anne Chapman, Ph.D., and colleagues with the ...
... 2008 -- In a study to examine the impact of ... report over one month, researchers at Columbia University Mailman School ... was a more accurate predictor of physically and mentally unhealthy ... to lose weight was more predictive of unhealthy days among ...
... to treatment than those with HPV-negative tumors , , TUESDAY, ... patients whose tumors test positive for human papillomavirus (HPV) ... than those who test negative, a new study says. ... be responsible for most cervical cancers, has recently been ...
Cached Medicine News:Health News:DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger 2Health News:AtriCure to Present at Roth Capital Partners 20th Annual OC Conference 2Health News:Other highlights in the Feb. 12 JNCI 2Health News:Other highlights in the Feb. 12 JNCI 3Health News:Other highlights in the Feb. 12 JNCI 4Health News:Body image is stronger predictor of health than obesity, says Mailman School of PH study 2
Nucleus Hydrodissection Cannula, 25 g. Angled with flattened tip. 7 mm angled shaft with flattened tip for insertion under the capsular flap. Overall length 19 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Angled with right hook. 10 mm angled shaft with 2.5 mm right hook tip. Overall length 20 mm. 5/box....
Retinal Hydrodissection Cannula. 20 gauge shaft tapers to 41 gauge I.D. flexible tip. Packaged sterile. 5/Box....
Irrigating Capsulorhexis Cystotome. Formed angled tip, 27 g. Overall length 16 mm. 5/box....
Medicine Products: